Torsdag 26 Februari | 03:33:06 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-12 07:00 Kvartalsrapport 2026-Q3
2026-08-19 07:00 Kvartalsrapport 2026-Q2
2026-05-14 07:00 Kvartalsrapport 2026-Q1
2026-04-23 N/A Årsstämma
2026-03-03 07:00 Bokslutskommuniké 2025
2026-01-02 - Extra Bolagsstämma 2026
2025-11-12 - Extra Bolagsstämma 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning LIFE 0.00 NOK
2025-04-25 - Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av microsensorer för diabetes. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-07 09:44:00

Reference is made to the stock exchange announcement published by Lifecare ASA (the "Company") on 7 January 2026, regarding the commencement of the subscription period in the partially underwritten rights issue (the "Rights Issue").

In connection with the Rights Issue, subscription rights have been allocated to existing shareholders as of 2 January 2026 (record date 6 January 2026), based on their registered shareholdings in the Company. Each existing share entitled the holder to 10.49 subscription rights, rounded down to the nearest whole subscription right. Each subscription right gives the right to subscribe for and be allocated one (1) new share in the Rights Issue at a subscription price of NOK 0.50 per share.

Subscription rights have been allocated to the following primary insiders and/or persons closely associated with them:

  • Teigland Eiendom AS, a company closely associated with Trine Teigland, board member of the Company, has been allocated 23,100,406 subscription rights.
  • Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company, has been allocated 187,739 subscription rights.
  • Tone Kvåle, board member of the Company, has been allocated 48,421 subscription rights.
  • Joacim Holter, CEO of the Company, has been allocated 236,434 subscription rights.
  • Cimter AS, a company closely associated with Joacim Holter, CEO of the Company, has been allocated 941,718 subscription rights.
  • Islay Venture GmbH, a company closely associated with Andreas Pfützner, CSO of the Company, has been allocated 1,410,747 subscription rights.

The allocation of subscription rights is made automatically and free of charge to existing shareholders in accordance with the terms of the Rights Issue and does not involve any consideration paid by the recipients.

Following the allocation of subscription rights, the shareholdings of the above-mentioned primary insiders and/or their closely associated persons remain unchanged.